Mass Spectrometry A key feature of monoclonal antibody (mAb) proteins is their stability in plasma due to their resistance to proteases.
All articles
Mass Spectrometry A key feature of monoclonal antibody (mAb) proteins is their stability in plasma due to their resistance to proteases.
Mass Spectrometry Subunit analysis of Zynlonta using a SCIEX X500B Mass Spectrometer
Mass Spectrometry
Mass Spectrometry Antibody drug conjugates (ADCs) combine a monoclonal antibody (mAb) scaffold with a number of cytotoxic drugs.
ADCs Sterling Pharma Solutions today announced a £1 million expansion project at its Deeside, UK site, which is the company’s dedicated bioconjugation and antibody-drug conjugates (ADCs) facility. The project will increase the current laboratory space from 275 to 419 square meters and establish cGMP bioconjugation/ADC manufacturing capabilities.
Mass Spectrometry Native intact analysis of Brentuximab Vedotin using a SCIEX X500B Mass Spectrometer
Mass Spectrometry
ADCs
Mass Spectrometry Explore more
Sign up for updates
Be the first to see the latest articles and updates from industry leaders, delivered straight to your inbox